Klotho Neurosciences, INC 8-K filings

Klotho Neurosciences announced a significant warrant repricing and a low-priced stock sale, alongside promising pre-clinical study findings on its s-KL protein for increasing longevity and health span.

Klotho Neurosciences, Inc. announced that its stockholders have approved a proposal to effect a reverse stock split of the company's common stock at a ratio between one-for-2 and one-for-50.

Klotho Neurosciences receives another notice from Nasdaq regarding non-compliance with listing rules, adding complexity to its ongoing efforts to regain compliance.

Klotho Neurosciences receives an extension from Nasdaq until August 13, 2025, to regain compliance with listing rules, subject to achieving specific milestones.

Klotho Neurosciences, Inc. will acquire SB Security Holdings, LLC, a subsidiary of SkyBell Technologies, Inc., in exchange for 90% of Klotho's common stock.

Klotho Neurosciences, Inc. received a delisting notice from Nasdaq due to non-compliance with minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements, and has requested a hearing to appeal the decision.

Klotho Neurosciences enters into a securities purchase agreement for a $2 million investment involving convertible notes and warrants with an institutional investor.

Klotho Neurosciences has entered into a convertible note agreement for $1.2 million with Austria Capital LLC, which includes an inducement of 2 million common shares.

Klotho Neurosciences has appointed seasoned healthcare executive Riad El-Dada to its Board of Directors, effective November 19, 2024.

Klotho Neurosciences, Inc. has terminated a licensing agreement with Teleost Biopharmaceuticals, LLC, as the licensed rights are no longer core to the company's business and research plans.

Klotho Neurosciences has terminated its engagement with Yusufali & Associates as its independent auditor due to the firm's disqualification by the Public Company Accounting Oversight Board and has appointed BCRG Group as its new auditor.

Klotho Neurosciences has entered into a new three-year employment agreement with CEO Dr. Joseph Sinkule, including a base salary of $360,000 and 1,000,000 stock options.

Klotho Neurosciences received a delisting notice from Nasdaq due to its stock price falling below $1 for 30 consecutive days, requiring the company to regain compliance by April 14, 2025.

Klotho Neurosciences, a biotech company focused on neurodegenerative diseases, has appointed Dr. Robert Langer, co-founder of Moderna, to its Scientific Advisory Board.

Edward Cong Wang resigned from ANEW Medical's Board of Directors on August 25, 2024.

ANEW Medical has appointed Jeffrey LeBlanc as Chief Financial Officer and Peter Moriarty as Chief Operating Officer, both effective August 15, 2024.

ANEW Medical, Inc. has received delisting notices from Nasdaq for failing to meet minimum market value requirements and has until February 12, 2025, to regain compliance.

ANEW Medical's interim Chief Financial Officer, Edward Cong Wang, resigned on July 30, 2024, but will remain a Director of the company.

Anew Medical, Inc. has completed its business combination with Redwoods Acquisition Corp., resulting in the company's shares and warrants trading on the Nasdaq under the symbols WENA and WENAW, respectively.

Redwoods Acquisition Corp. has filed an 8-K report detailing a re-audit of ANEW Medical's financials and providing an update on their business combination agreement.

Redwoods Acquisition Corp. has amended its previous filing to correct the redemption price per share to $10.78 and announced a forward purchase agreement with Meteora Capital Partners.

Redwoods Acquisition Corp. has entered into a forward purchase agreement and a subscription agreement with Meteora Capital, involving the potential purchase of up to 1,000,000 shares and other financial arrangements.

Redwoods Acquisition Corp. has entered into a non-redemption agreement with certain investors to reverse their redemption requests for up to 360,000 shares, aiming to proceed with its business combination with ANEW MEDICAL, INC.

Redwoods Acquisition Corp. stockholders have approved the business combination with ANEW MEDICAL, Inc., paving the way for the merger and name change to ANEW MEDICAL, INC.

Redwoods Acquisition Corp. adjourned its special meeting of stockholders without conducting any business and rescheduled it for April 12, 2024, allowing shareholders to withdraw redemption requests.

Redwoods Acquisition Corp. has adjourned its special meeting of stockholders to April 8, 2024, without conducting any business, and is allowing shareholders to reverse redemption requests.

Redwoods Acquisition Corp. has adjourned its special meeting of stockholders to April 1, 2024, allowing shareholders to withdraw redemption requests.

Redwoods Acquisition Corp. has adjourned its special meeting to vote on the proposed merger with ANEW Medical Inc. to March 22, 2024, allowing shareholders to reverse redemption requests.